Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers

Insilico Medicine Expands Synthetic Lethality Portfolio With Nomination Of A Preclinical Candidate Targeting Mat2a For The Treatment Of Mtap Deleted Cancers

Facebook Comments

Leave a Reply

CommentLuv badge